Search

Over the past decade, targeted therapy for oncogene-driven NSCLC and immune checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved the survival and quality of life for patients with unresectable NSCLC. Increasingly, these biomarker-guided systemic therapies given before or after surgery have been used in patients with early-stage NSCLC. In March 2022, the US FDA granted the approval of neoadjuvant nivolumab and chemotherapy for patients with stage IB-IIIA NSCLC. Several phase II/III trials are evaluating the clinical efficacy of various neoadjuvant immune checkpoint inhibitor combinations for non-oncogene-driven NSCLC and neoadjuvant molecular targeted therapies for oncogene-driven NSCLC, respectively. However, clinical application of precision neoadjuvant treatment requires a paradigm shift in the biomarker testing and multidisciplinary collaboration at the diagnosis of early-stage NSCLC. In this comprehensive review, we summarize the current diagnosis and treatment landscape, recent advances, new challenges in biomarker testing and endpoint selections, practical considerations for a timely multidisciplinary collaboration at diagnosis, and perspectives in emerging neoadjuvant precision systemic therapy for patients with resectable, early-stage NSCLC. These biomarker-guided neoadjuvant therapies hold the promise to improve surgical and pathological outcomes, reduce systemic recurrences, guide postoperative therapy, and improve cure rates in patients with resectable NSCLC.

Immunotherapy has become the central pillar of cancer therapy. Immune checkpoint inhibitors (ICIs), a major category of tumor immunotherapy, reactivate preexisting anticancer immunity. Initially, ICIs were approved only for advanced and metastatic cancers in the salvage setting after or concurrent with chemotherapy at a response rate of around 20–30% with a few exceptions. With significant progress over the decade, advances in immunotherapy have led to numerous clinical trials investigating ICIs as neoadjuvant and/or adjuvant therapies for resectable solid tumors. The promising results of these trials have led to the United States Food and Drug Administration (FDA) approvals of ICIs as neoadjuvant or adjuvant therapies for non-small cell lung cancer, melanoma, triple-negative breast cancer, and bladder cancer, and the list continues to grow. This therapy represents a paradigm shift in cancer treatment, as many early-stage cancer patients could be cured with the introduction of immunotherapy in the early stages of cancer. Therefore, this topic became one of the main themes at the 2021 China Cancer Immunotherapy Workshop co-organized by the Chinese American Hematologist and Oncologist Network, the China National Medical Products Administration and the Tsinghua University School of Medicine. This review article summarizes the current landscape of ICI-based immunotherapy, emphasizing the new clinical developments of ICIs as curative neoadjuvant and adjuvant therapies for early-stage disease.

The combination of LiDAR and camera modalities is proven to be necessary and typical for 3D object detection according to recent studies. Existing fusion strategies tend to overly rely on the LiDAR modal in essence, which exploits the abundant semantics from the camera sensor insufficiently. However, existing methods cannot rely on information from other modalities because the corruption of LiDAR features results in a large domain gap. Following this, we propose CrossFusion, a more robust and noise-resistant scheme that makes full use of the camera and LiDAR features with the designed cross-modal complementation strategy. Extensive experiments we conducted show that our method not only outperforms the state-of-the-art methods under the setting without introducing an extra depth estimation network but also demonstrates our model's noise resistance without re-training for the specific malfunction scenarios by increasing 5.2\% mAP and 2.4\% NDS.

Additional file 5.

Additional file 6.

Additional file 9.

Additional file 5.

Additional file 9.

Additional file 8.

Additional file 6.

Additional file 7.

Additional file 7.

Additional file 8.

The corrosion resistance of MoNb/AlNd/MoNb film during different sputter conditions was studied for G6 rotating target sputter equipment. The results show that with the increase of sputter power and the increase of the thickness, top MoNb tends to form coarse columnar crystals, and the corrosion resistance of the metal thin films, at first, increases and then decreases with the increase of sputter power and metal thickness. As the sputter temperature increases, top MoNb tends to form coarse grains while the corrosion resistance of the film is poor. The result also release that with the increase of the target speed, top MoNb film becomes loose so that it is difficult to play a protective role because of its poor corrosion resistance ability. Under the same conditions, the sputter of the planar target film is denser; as a result, the top MoNb layer can protect the inner AlNd layer from corrosion.

In C-NCAP(2012 version) , P3 child dummy is added in 100% frontal impact test to evaluate child restraint system. With the development of vehicle's passive safety, more attention is paid to child passenger's injure. First, this paper discusses the child dummy injury evaluation method in current test conditions and the rear child dummy injury situation by different test data. At the same time, it studies the influence to child dummy's injure of different rear safe seats and other factor, which is very useful.